GE Medical Systems has signed a clinical trial agreement with the National Cancer Institute’s Cancer Imaging Program. The multisite clinical trials will evaluate 18F-fluorothymidine (FLT) as an agent for PET studies.
Used to image DNA synthesis, FLT has shown preliminary promise for the in-vivo imaging of cellular proliferation. The NCI will sponsor clinical trials at Johns Hopkins Medical Institutions, Virginia Commonwealth University Medical Center, Massachusetts General Hospital, the University of Washington, and the National Institutes of Health Clinical Center, according to Waukesha, WI-based GE.
The vendor will provide the sites with its TRACERlab FX synthesis systems for production of FLT. GE said it anticipates that FLT will be one of the first PET agents for which there will be a FDA investigational new drug (IND) proceeding for the NCI-sponsored multi-site trials. The clinical trials are the first of an imaging agent being supported by GE.
By AuntMinnie.com staff writersNovember 24, 2003
Related Reading
GE expands capabilities of Infinia Hawkeye SPECT/CT, November 13, 2003
GE installs first Centricity 2.0 network, November 11, 2003
GE adds Centricity enterprise site, October 31, 2003
GE signs Catholic Health, October 21, 2003
GE signs Saint Francis, September 9, 2003
Copyright © 2003 AuntMinnie.com
